Med-Tech Innovation August 5, 2024
Oliver Johnson

Indica Labs, a leading provider of AI-powered digital pathology solutions, has announced the launch of Lung Macrodissect AI, a tool that the company says ‘revolutionises’ sli­­de macrodissection and molecular pathology workflows.

The company says Lung Macrodissect AI represents a significant leap forward for the integration of artificial intelligence with digital pathology by offering pathologists a streamlined macrodissection workflow that minimises human error and improves efficiency.

Lung Macrodissect AI is deployed in HALO AP, quantifies tumour content, streamlines tumour annotation, and ensures specimen quality for downstream analysis according to Indica.

Tumour content estimation and macrodissection are critical steps in molecular pathology, involving the assessment of tumour content within a sample and the precise isolation and removal of tumour regions for downstream...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Medical Devices, Provider, Technology
Related Articles:
UN warns of military brain control
Only 20% of AI devices for children used pediatric data to train: 3 notes
Medtech firms have cut thousands of jobs this year. Will layoffs continue in 2025?
Proton therapy market in the US projected to reach $2.67 billion by 2033
How Trump’s second term will affect the medtech industry

Share This Article